Tirofiban and Enoxaparin in High Risk Coronary Intervention
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Patients undergoing coronary angioplasty are frequently treated with new drugs that stop
blood platelets working and so improve the success of the procedure. Individual patients may
vary in the dose of the drug required. New platelet tests have been developed which can be
performed near the patient and possibly immediately tell the doctor the degree of platelet
inhibition achieved so that the dose can be adjusted accordingly. This study aims to
investigate if these platelet tests indicate if new anticoagulants are more effective at
inhibiting platelet function than the traditional anticoagulants. The study will demonstrate
if these newer drugs improve blood flow through the heart muscle and thereby provide better
long term outcomes for patients undergoing percutaneous intervention.